Syncom Formulations (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Syncom Formulations |
|||
|
Price: ₹19.81 | ||
| 52 Week Low: ₹10.95 52 Week High: ₹27.90 |
|||
| Market Capital: 1,224.82 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Syncom Formulations Share Price Target For 2024
- 1.1.1: Syncom Formulations Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Syncom Formulations Share Price Target For 2025
- 1.2.1: Syncom Formulations Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Syncom Formulations Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Syncom Formulations Brief Company Overview
- 4: Syncom Formulations Financial Performance
- 4.0.1: Is Syncom Formulations A Good Buy For Long Term?
To predict the Syncom Formulations's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Syncom Formulations Share Price Target For 2024
The line chart displays the monthly closing prices of Syncom Formulations with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Syncom Formulations shares in 2024, see the table below.
Syncom Formulations Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 20.89 (+5.45%) | Price Action: 18 Dec 2024 Low |
| 2024 Target 2 | 20.68 (+4.38%) | Technical Indicator: MA50 |
| 2024 Target 1 | 20.47 (+3.33%) | Price Action: 11 Nov 2024 High |
| Current Price | 19.81 | Syncom Formulations's share price as of 26 Dec 2024 |
| Stop Loss 1 | 19.51 (-1.52%) | Price Action: 25 Nov 2024 Low |
| Stop Loss 2 | 19.2 (-3.08%) | Price Action: 29 Aug 2024 Low |
| Stop Loss 3 | 19.0 (-4.09%) | Price Action: 22 Oct 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Syncom Formulations is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹20.65 serves as the nearest technical reference point.
Historical Returns: 3-month: -9.17% | 6-month: +58.73% | 1-year: +31.63%
Syncom Formulations Share Price Target For 2025
The line chart displays the monthly closing prices of Syncom Formulations with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Syncom Formulations shares in 2025, see the table below.
Syncom Formulations Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 31.99 (+61.48%) | Fibonacci Extension Level 123.60% |
| 2025 Target 2 | 31.38 (+58.4%) | Price Action: Chart |
| 2025 Target 1 | 31.07 (+56.83%) | Fibonacci Extension Level 64.90% |
| Current Price | 19.81 | Syncom Formulations's share price as of 26 Dec 2024 |
| Stop Loss 1 | 17.2 (-13.18%) | Price Action: 30 Jan 2024 High |
| Stop Loss 2 | 17.0 (-14.19%) | Price Action: 13 Aug 2024 High |
| Stop Loss 3 | 16.82 (-15.1%) | Technical Indicator: MA200 |
Long-Term Technical Outlook
52-Week Range Analysis: Syncom Formulations is currently trading at 52.3% of its 52-week range (₹10.95 - ₹27.9).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +31.63% | 3-year: +50.53% | 5-year: +2,541.33%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Syncom Formulations Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹19.81 | ||
| 2024 | ₹22.38 | +12.97% | ₹22.72 |
| 2025 | ₹35.33 | +57.86% | ₹37.46 |
| 2026 | ₹47.15 | +33.45% | ₹47.99 |
| 2027 | ₹64.61 | +37.03% | ₹65.58 |
| 2028 | ₹74.53 | +15.35% | ₹75.65 |
| 2029 | ₹82.52 | +10.72% | ₹88.03 |
| 2030 | ₹97.07 | +17.63% | ₹98.70 |
| 2031 | ₹108.21 | +11.47% | ₹109.83 |
| 2032 | ₹131.06 | +21.11% | ₹133.03 |
| 2033 | ₹138.11 | +5.37% | ₹140.18 |
| 2034 | ₹142.66 | +3.29% | ₹155.46 |
| 2035 | ₹158.81 | +11.32% | ₹172.31 |
| 2036 | ₹169.27 | +6.58% | ₹181.81 |
| 2037 | ₹197.52 | +16.68% | ₹200.48 |
| 2038 | ₹201.69 | +2.11% | ₹206.03 |
| 2039 | ₹189.19 | -6.19% | ₹222.89 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Syncom Formulations Brief Company Overview
Syncom Formulations (India) Limited: A Trusted Pharmaceutical Manufacturer Syncom Formulations (India) Limited, established in 1988, is a leading pharmaceutical manufacturer headquartered in Indore, India. The company boasts a diverse product portfolio that includes...
antibiotics, anthelmintics, cardiac, derma, and pediatrics formulations. Syncom's commitment to quality and innovation has earned it a strong reputation in the industry. Its pharmaceutical formulations are available in various dosage forms, catering to a wide range of therapeutic needs. The company also engages in commodity trading and property renting. Key Products: Pharmaceutical formulations, antibiotics, anthelmintics, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations Services: Trading of commodities, renting of properties Market Presence: Exports products to various countriesSyncom Formulations Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,224.82 Crore | Market valuation of Syncom Formulations's shares. |
| Revenue (TTM) | 249.79 Crore | Total revenue generated by Syncom Formulations over the past twelve months. |
| Net Income (TTM) | +26.38 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +9.07% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +10.56% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+13.5% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+68.89% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
29.64 | Company's total debt divided by total shareholder equity. |
| Total Debt | 80.08 Crore | Sum of Syncom Formulations's current & long-term financial obligations. |
| Total Cash | 61.38 Crore | Total amount of liquid funds available to Syncom Formulations. |
| Beta | 1.27 | Beta is greater than 1 indicating that the Syncom Formulations's price is more volatile than the market. |
Is Syncom Formulations A Good Buy For Long Term?
Syncom Formulations, a small-cap stock with a market cap of 1,224.82 Crore, has shown promising growth in the last 12 months, generating a revenue of 249.79 Crore and a net profit of 26.38 Crore. Its strong revenue and earnings growth, along with healthy margins, indicate potential for long-term growth. Despite a current debt of 80.08 Crore, the company's cash balance of 61.38 Crore provides financial stability. Investors looking for a long-term investment opportunity in the pharmaceuticals sector may consider Syncom Formulations.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
